NewsBenzingaCandel Therapeutics Announces Immunological Biomarker Data From Ongoing Phase 2 Prtk05 Trial In Patients With Intermediate-Risk Localized Prostate Cancer Candel Therapeutics Announces Immunological Biomarker Data From Ongoing Phase 2 Prtk05 Trial In Patients With Intermediate-Risk Localized Prostate Cancer Benzinga 2026.09.30 12:33 (GMT+0) Open on Benzinga Other news Homebuilder Sentiment Hits 2012 Lows As Stocks Trade Like They Did During COVID-19 Pandemic Rain Says Western Union's Stablecard Is Live in 37 Markets FDA Clears GSK Drug That Could Change How Certain Rectal Cancers Are Treated Nvidia Researchers Using Supercomputer Jupiter For Fault-Tolerant Computing Simulation Gilead Bolsters Inflammatory Bowel Disease Pipeline With Promising Mid-Stage Trial Success SpaceX Stock Shakeup: Elon Musk’s Stock Giveaway Meets Insider Sales
